Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May;36(5):1436-1439.
doi: 10.1038/s41375-022-01537-w. Epub 2022 Mar 11.

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Bengt Rasmussen  1 , Gudrun Göhring  2 , Elsa Bernard  3 , Lars Nilsson  4 , Magnus Tobiasson  5 , Martin Jädersten  5 , Hege Garelius  6 , Ingunn Dybedal  7 , Kirsten Grønbaek  8 , Elisabeth Ejerblad  9 , Fryderyk Lorenz  10 , Max Flogegård  11 , Claus Werenberg Marcher  12 , Annette Öster Fernström  13 , Lucia Cavelier  14 , Elli Papaemmanuil  3 , Freja Ebeling  15 , Astrid Olsnes Kittang  16 , Jan Maxwell Nørgaard  17 , Leonie Saft  18 , Lars Möllgård #  6 , Eva Hellström-Lindberg #  19
Affiliations
Clinical Trial

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Bengt Rasmussen et al. Leukemia. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Overall Survival was analyzed by Kaplan-Meier, P-values derived from log-rank tests.
Number of patients indicated in parentheses. a Survival in patients treated with azacitidine (AZA) vs azacitidine + lenalidomide (AZA + LEN) (log-rank P = 0.43). b Survival comparison between patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) at inclusion (log-rank P = 0.002). c Survival among TP53 mutation subgroups; TP53 mono-allelic vs multi-hit vs TP53 wild-type (WT) (log-rank P = 0.0001).
See this image and copyright information in PMC

References

    1. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65. doi: 10.1056/NEJMoa061292. - DOI - PubMed
    1. Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183–8. doi: 10.1038/nature14610. - DOI - PMC - PubMed
    1. Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26:509–20. doi: 10.1016/j.ccr.2014.08.001. - DOI - PMC - PubMed
    1. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549–56. doi: 10.1038/s41591-020-1008-z. - DOI - PMC - PubMed
    1. Mollgard L, Saft L, Treppendahl MB, Dybedal I, Norgaard JM, Astermark J, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96:963–71. doi: 10.3324/haematol.2010.039669. - DOI - PMC - PubMed

Publication types

MeSH terms